SGEN/Takeda's Adcetris Progresses - Analyst Blog

By
A A A
Share |

Seattle Genetics Inc. ( SGEN ) and Takeda Pharmaceutical Company Limited ( TKPYY ) recently announced the commencement of a global phase III study (ECHELON-2) on their oncology treatment, Adcetris (brentuximab vedotin). Adcetris (brentuximab vedotin) plus chemotherapy will be evaluated for the front-line treatment of CD30-positive mature T-cell lymphoma (MTCL) including in patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

We note that study is being conducted under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) program. Seattle Genetics said that the European Medicines Agency (EMA) also provided scientific advice for the study. The randomized, double-blind, controlled study will enroll roughly 300 patients and will be conducted in North America, Europe and Asia.

Seattle Genetics and Takeda had presented encouraging phase I data on Adcetris at the American Society of Hematology (ASH) annual meeting in Dec 2012. Adcetris is currently approved in the US for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT and the treatment of sALCL in treatment-experienced patients. Adcetris is approved in the EU as well.

Our Take

We are positive on Seattle Genetics' efforts to expand Adcetris' label. Approval in the front-line setting will boost Adcetris' sales signifcantly. Adcetris net revenue in the third quarter of 2012 was $33.7 million and for the nine months ending Sep 30, 2012 was $102.8 million.

Seattle Genetics carries a Zacks Rank #3 (Hold). Right now Agenus Inc. ( AGEN ), Valeant Pharmaceuticals International, Inc. ( VRX ) and Targacept, Inc. ( TRGT ) look more attractive with a Zacks Rank #1 (Strong Buy).



AGENUS INC (AGEN): Free Stock Analysis Report

SEATTLE GENETIC (SGEN): Free Stock Analysis Report

(TKPYY): ETF Research Reports

TARGACEPT INC (TRGT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AGEN , ASH , SGEN , SPA , TKPYY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Form 990 Explained
Form 990 Explained                  

Stocks

Referenced

Most Active by Volume

119,887,279
  • $61.47 ▲ 0.18%
77,037,447
  • $3.185 ▲ 0.47%
60,915,565
  • $4.345 ▼ 1.70%
49,554,639
  • $16.3946 ▲ 0.15%
41,625,110
  • $87.62 ▲ 0.99%
33,122,138
  • $26.13 ▼ 0.46%
32,766,566
  • $46.20 ▼ 2.59%
29,788,058
  • $34.46 ▼ 1.32%
As of 4/24/2014, 03:20 PM